The Cancer Journal

Skip Navigation LinksHome > March/April 2010 - Volume 16 - Issue 2 > Poly(ADP-Ribose) Polymerase Inhibitors: A Novel Drug Class W...
Text sizing:
Cancer Journal:
doi: 10.1097/PPO.0b013e3181d78223
Practice of Oncology: Recent Advances

Poly(ADP-Ribose) Polymerase Inhibitors: A Novel Drug Class With a Promising Future

Gartner, Elaina M. MD*; Burger, Angelika M. PhD†; LoRusso, Patricia M. DO*

Collapse Box


Poly(ADP-ribose) polymerase inhibitors are an exciting new class of antineoplastic agents that impair the ability of cells to recover from DNA damage. They are most effective in the setting of inherent DNA repair defects, such as in cancers resulting from BRCA gene mutations, or in the setting of DNA-damaging chemotherapeutic agents. This article reviews the background and development of these agents in the laboratory, as well as the rationale for the biologic correlative studies used in clinical trials. The most recent data from the clinical trials of olaparib (AZD2281, KU-0059436), BSI-201, AG014699, ABT-888, and INO-1001 and descriptions of ongoing studies are also presented.

© 2010 Lippincott Williams & Wilkins, Inc.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.